Summary & Overview
HCPCS C9043: Levoleucovorin Injection, 1 mg
HCPCS Level II code C9043 denotes the injection of levoleucovorin, 1 mg, an injectable adjunct commonly used with certain chemotherapy agents to mitigate toxicity and support clinical outcomes. Nationally, accurate coding of parenteral oncology agents matters for clinical documentation, reimbursement consistency, and pharmacy-administration tracking. This brief addresses the clinical and billing context for C9043 and summarizes payer coverage considerations across major national payers.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and what to expect in payer coverage discussions. The publication outlines benchmark topics and policy-relevant points typically examined for injectable oncology adjuncts: billing unit definitions, site-of-care implications, and payer coverage variability.
The piece does not provide individualized reimbursement rates. Instead, it equips administrators and coding professionals with the core clinical description and the national payer landscape context needed to pursue coverage, verify claims, and align internal billing practices. Data not available in the input will be noted where applicable in subsequent sections.
Billing Code Overview
HCPCS Level II code C9043 describes the injection of levoleucovorin, 1 mg. This code represents a single-unit parenteral administration of levoleucovorin used in conjunction with certain chemotherapy regimens to reduce toxicity and enhance therapeutic effect.
-
Service type: Parenteral drug administration (injectable antidote/adjunct)
-
Typical site of service: Hospital outpatient department, infusion center, or clinic setting where oncology injections are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving leucovorin rescue after high-dose fluoropyrimidine (for example, high-dose 5-fluorouracil) or as part of combination chemotherapy where enhanced folinic activity is indicated. The patient presents to an outpatient infusion clinic or hospital outpatient infusion center for administration. The medication C9043 (injection, levoleucovorin, 1 mg) is prepared by pharmacy and verified by a pharmacist. The nurse performs standard pre-administration checks: verifies patient identity, reviews allergy and medication history, confirms chemotherapy orders and dose calculation, inspects the IV line for patency, and documents baseline vital signs. The nurse administers C9043 either as an intravenous bolus or short infusion per protocol, observes the patient for immediate adverse reactions, and documents administration time, lot number, and amount. Post-administration monitoring includes vital sign reassessment and assessment for expected therapeutic effect or adverse events. Billing for C9043 is submitted by the facility or provider with appropriate encounter details and diagnosis linkage to the underlying oncologic or toxicity-related ICD-10 code.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
24 | Unrelated evaluation and management service by the same physician during a postoperative period |